Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical observation of hepatic portal vein ligation (PVL) combined with apatinib and Camrelizumab transformation in the treatment of patients with primary hepatocellular carcinoma with residual liver volume

X
Trial Profile

Clinical observation of hepatic portal vein ligation (PVL) combined with apatinib and Camrelizumab transformation in the treatment of patients with primary hepatocellular carcinoma with residual liver volume

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms PLACES
  • Most Recent Events

    • 08 Nov 2022 Status changed to completed, as per results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 08 Nov 2022 Results assessing the efficay and safety of hepatic portal vein ligation combined with Apatinib and Camrelizimabin conversion of HCC with insufficient FLR to resectable hepatocellular Carcinoma, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 08 Jun 2021 Results (n=14) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top